Early response and 8-week treatment outcome in GAD.
Early response and 8-week treatment outcome in GAD.
复制标题
GAD 的早期缓解和 8 周治疗结果。
DOI：
10.1002/da.20214
复制
发表时间：
2006
影响因子：
7.4
通讯作者：
Rickels,Karl
中科院分区：
文献类型：
--
作者：
Rynn,Moira;Khalid-Khan,Sarosh;Garcia-Espana,JFelipe;Etemad,Bijan;Rickels,Karl
我们的目的是比较广泛性焦虑症（GAD）患者接受苯二氮卓类药物、5-羟色胺受体（5 HT-1A）部分激动剂或安慰剂治疗后早期反应对治疗结局的预测价值。合并了两项双盲GAD研究的数据。在8周内使用汉密尔顿焦虑量表（HAM-A）和临床疗效总评量表（CGI-I）对受试者进行评价。第1周和第2周的缓解类别由HAM-A总分定义。协方差分析和Kaplan-Meier生存分析是用于评估作为早期改善函数的8周终点治疗结局的主要分析。HAM-A从基线到第1周和第2周的变化显著预测了两种药物和安慰剂在第8周的末次观察值结转（LOCF）反应（P<.001）。早期改善是治疗结果的强预测因子，无论活性药物或安慰剂是否为治疗药物。抑郁和焦虑23：461-465，2006. 2006年出版Wiley利斯公司
Our objective was to compare the predictive value of early response to treatment outcome in patients with generalized anxiety disorder (GAD) treated with benzodiazepines, serotonin receptor (5HT‐1A) partial agonists, or placebo. Data from two double‐blind GAD studies were combined. Subjects were evaluated with the Hamilton Anxiety Scale (HAM‐A) and the Clinical Global Impression of Improvement (CGI‐I) scale over 8 weeks. Categories of response at weeks 1 and 2 were defined by the HAM‐A total score. Analyses of covariance and Kaplan–Meier survival analyses were the primary analyses used to assess 8‐week end point treatment outcomes as a function of early improvement. HAM‐A change from baseline to weeks 1 and 2 significantly predicted last observation carried forward (LOCF) response at week 8 for both medications and for placebo (P<.001). Early improvement was a strong predictor for treatment outcome irrespective of whether active medication or placebo was the treatment agent. Depression and Anxiety 23:461–465, 2006. Published 2006 Wiley‐Liss, Inc.